
LGND • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold LGND in your mock portfolio yet.
A PE ratio of 84.44 against EPS of 2.27 implies a rich valuation that prices in strong future growth or highly recurring, high‑margin revenues. However, without evidence of rapid earnings expansion, such a multiple can be vulnerable to compression. On balance, the financial picture looks fundamentally sound but expensive, leading to a neutral stance.
The stock trades at $191.69, meaningfully above its 200‑day moving average of $158.13, indicating a sustained uptrend despite a 4.2% pullback over the last month. An RSI of 63.08 shows positive momentum but is approaching overbought territory, suggesting upside may be more incremental and vulnerable to short‑term corrections. Overall, the technical setup is constructive but not at an ideal low‑risk entry point.
Website traffic at about 4,980 monthly visitors and only 1 job opening with flat growth suggest a relatively stable but not aggressively expanding operational footprint. Social media data is mixed: a slight decline in Twitter/X followers and a modest increase on LinkedIn point to stable but not rapidly accelerating engagement. These signals do not strongly confirm either a bullish or bearish inflection in the business outlook.
Overall, the picture for Ligand Pharmaceuticals appears neutral: the stock is in a clear uptrend and trades above its 200‑day moving average, but valuation is demanding and momentum is already strong, limiting near‑term upside without further fundamental catalysts. Alternative data signals point to a steady rather than rapidly accelerating business footprint, which does not fully justify a strongly bullish stance at the current price.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: